Tetrahydrocannabivarin may be beneficial in typ 2 diabetes according to a clinical study

Tetrahydrocannabivarin may be beneficial in typ 2 diabetes according to a clinical study

By: IACM Medical

The plant cannabinoid THCV (tetrahydrocannabivarin) decreases glucose levels and may have further beneficial effects in patients with type 2 diabetes. This is the result of research by scientists from Nottingham, London and Oxford in the UK, published in Diabetes Care. They included 62 patients with noninsulin-treated type 2 diabetes in a placebo-controlled study with CBD (100 mg twice daily), THCV (5 mg twice daily), a combination of CBD and THCV (5 mg of both cannabinoids twice daily), and a 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily).

Compared with placebo, THCV significantly decreased fasting plasma glucose and improved the function of cells in the pancreas, which are responsible for insulin production (HOMA2 beta-cell function). It also improved the values for adiponectin and apolipoprotein A. There was no difference between CBD and placebo. None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated. Authors concluded that “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”

Check the study here.

Source: http://www.cannabis-med.org/english/bulletin/iacm.php

Kannabia Seeds Company sells to its customers a product collection, a souvenir. We cannot and we shall not give growing advice since our product is not intended for this purpose.

Kannabia accept no responsibility for any illegal use made by third parties of information published. The cultivation of cannabis for personal consumption is an activity subject to legal restrictions that vary from state to state. We recommend consultation of the legislation in force in your country of residence to avoid participation in any illegal activity.